Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenicEscherichia coliandProteus mirabilis

A porcine reproductive and respiratory syndrome virus (PRRSV) vaccine candidate based on the fusion protein of PRRSV glycoprotein 5 and the Toll-like Receptor-5 agonist Salmonella Typhimurium FljB

(2015) Dan Xiong et al.   BMC Veterinary Research

Urinary tract infection of mice to model human disease: Practicalities, implications and limitations

(2015) Alison J. Carey et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model

(2015) Mehri Habibi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis

(2015) Mehri Habibi et al.   MOLECULAR IMMUNOLOGY

Urinary tract infections: epidemiology, mechanisms of infection and treatment options

(2015) Ana L. Flores-Mireles et al.   NATURE REVIEWS MICROBIOLOGY

A truncated fragment of Ov-ASP-1 consisting of the core pathogenesis-related-1 (PR-1) domain maintains adjuvanticity as the full-length protein

(2015) Jingjing Guo et al.   VACCINE

Cutting Edge: FimH Adhesin of Type 1 Fimbriae Is a Novel TLR4 Ligand

(2014) K. L. Mossman et al.   JOURNAL OF IMMUNOLOGY

Innate immune responses to Proteus mirabilis flagellin in the urinary tract

(2013) Ana Umpiérrez et al.   MICROBES AND INFECTION

Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice

(2013) Mohammad Reza Asadi Karam et al.   VACCINE

Uncomplicated Urinary Tract Infection

(2012) Thomas M. Hooton   NEW ENGLAND JOURNAL OF MEDICINE

Molecular blueprint of uropathogenicEscherichia colivirulence provides clues toward the development of anti-virulence therapeutics

(2012) Maria Kostakioti et al.   Virulence

FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice

(2011) Mohamed F. Abdul-Careem et al.   ANTIVIRAL RESEARCH

Trends in vaccine adjuvants

(2011) Virgil EJC Schijns et al.   Expert Review of Vaccines

FimH Can Directly Activate Human and Murine Natural Killer Cells via TLR4

(2010) M Firoz Mian et al.   MOLECULAR THERAPY

Host–pathogen interactions in urinary tract infection

(2010) Greta R. Nielubowicz et al.   Nature Reviews Urology

Waging War against Uropathogenic Escherichia coli: Winning Back the Urinary Tract

(2009) K. E. Sivick et al.   INFECTION AND IMMUNITY

A Live‐Attenuated Vaccine for the Treatment of Urinary Tract Infection by UropathogenicEscherichia coli

(2009) Benjamin K. Billips et al.   JOURNAL OF INFECTIOUS DISEASES

Current concepts of molecular defence mechanisms operative during urinary tract infection

(2008) T. Weichhart et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Innate and adaptive immune responses in the urinary tract

(2008) J. Song et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections

(2008) B. Ragnarsdóttir et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

FimH Adhesin of Type 1 Fimbriae Is a Potent Inducer of Innate Antimicrobial Responses Which Requires TLR4 and Type 1 Interferon Signalling

(2008) Ali A. Ashkar et al.   PLoS Pathogens